BioSpace News Archive

Congratulations go out to the Lupus Research Alliance advocates!

Sutro Biopharma, Inc. today announced the pricing of its initial public offering of 5,667,000 shares of its common stock at a price to the public of $15.00 per share.

The agreement will bolster Lilly’s industry-leading diabetes portfolio

The Biologics License Application for SB5 was based on a 52-week Phase 3 study comparing SB5 to the adalimumab reference product

Upon the passage of the fiscal year (FY) 2019 Healthy and Human Services (HHS) budget with an additional $425 million designated for Alzheimer’s disease research—bringing the federal funding to fight Alzheimer’s to a total of $2.34 billion—The Alzheimer’s Foundation of America (AFA) issued the following statement from Charles J. Fuschillo, Jr., AFA’s president and CEO

The Hyundai Hope On Wheels Foundation embarks on a nationwide tour this September in honor of National Childhood Cancer Awareness Month to award $14.1 million to 38 researchers, surpassing $145 million in total giving.

Galapagos NV (Euronext & NASDAQ: GLPG) reports first dosing in the global ROCCELLA Phase 2 trial with GLPG1972/S201086 in knee osteoarthritis patients.

Nightstar Therapeutics plc, announced that positive preliminary safety and efficacy data of NSR-RPGR from the dose escalation study in the Phase 1/2 XIRIUS trial were presented today at the EURETINA 2018 Congress.

Alzheimer’s Research UK, is calling on the UK government to adopt a bold new action plan to bring about a life-changing dementia treatment and improve the lives of people with the condition.

Pacey MedTech Ltd., a Vancouver-based company, today announced that they have created the Pacey Cuff™, a urethral control device (UCD) that is an effective and reliable solution to urinary incontinence (UI) in men.